TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04164719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Description: Subjects will place TNX-102 SL sublingual tablets under the tongue until dissolved, and not to crush or chew them
Study: NCT00912041

Intervention type: DEVICE
Group type: OTHER
Intervention: Placement of the BrainGate2 sensor(s) into the motor-related cortex
Description: Up to four 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex (including speech-related areas of cortex), connected to one or two percutaneous pedestals. Neural recordings are made at least weekly for a year or more.
Study: NCT01891110

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ES of the abdominal muscles
Description: ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ES of the limb muscles
Description: Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ES of limbs & abdomen
Description: The combination of the ES of the lower limb muscles and the abdominal muscles.
Study: NCT04357470

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Hand Therapy
Description: The patients were admitted to 12-weeks rehabilitation program and were called up once a week for follow-up appointments. Hand therapy continued as home program between 12th week and 6th month.
Study: NCT02855073

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ReJoinTM
Description: adipose derived mesenchymal progeinitor cells

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Sodium Hyaluronate Injection
Study: NCT03637023

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Virtual Reality Based Rehabilitation including static balance, dynamic balance and walking

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: The conventional physical Therapy program includes parameters for improving strength, flexibility, transfers, posture, balance and coordination, and sensory stimulation. These activities consist of various types of exercises that focus on lower extremity movements.
Study: NCT03084731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Directed Complementary Food (MDCF)
Description: For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period.
Study: NCT02801578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
Study: NCT02923167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted training of the hand
Description: Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant's fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
Study: NCT00829465

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Licartin
Description: Licartin

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transcatheter arterial chemoembolization
Description: TACE

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter arterial chemoembolization
Description: TACE
Study: NCT03412591

Intervention type: DRUG
Group type: OTHER
Intervention: Suvorexant 20 mg
Description: Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.

Intervention type: DRUG
Group type: OTHER
Intervention: Suvorexant 20 mg
Description: Suvorexant 20 mg is an orexin 1/2receptor antagonist approved for the treatment of sleep disturbance in subjects with Primary Insomnia.
Study: NCT05460286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chiropractic Manipulation
Description: 20 participants with low back pain existing more than 3 months was included in the CSMT group. Lumbar region chiropractic HVLA (High Velocity, Low Amplitude) spinal manipulation and/or sacroiliac joint chiropractic HVLA manipulation were applied to participants. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Decompression Device Treatment
Description: 20 participants with low back pain existing more than 3 months was included in the SD group. Lumbar region spinal decompression (traction) device therapy was applied to participants, and as a standard of treatment was given a hot pack for 15 minutes before applying and a cold pack for 10 minutes after applying. Participants were treated three times with an interval of three days. Before and after treatment were evaluated lower extremity (hamstring and quadriceps) muscle strength with an isokinetic dynamometer (CSMI Humac-Norm), balance performance with BBS (Biodex Balance System), lumbar range of motion and mobility with inclinometer and hand finger floor distance (HFFD), low back pain intensity with visual analog scale (VAS), functional status with Modified Oswestry low back pain disability questionnaire (OSW), quality of life with Short form-36 (SF-36).
Study: NCT02108808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel or Clopidogrel
Study: NCT03590548

Intervention type: DIAGNOSTIC_TEST
Intervention: gausher disease
Description: lab investigation and radio logical
Study: NCT01484756

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: daily multi micronutrient supplement
Description: Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: calcium carbonate 500 mg
Study: NCT05115773

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intraligamentary anaesthesia
Description: one tooth anaesthesia by 2 or 4 points intraligamentary injection

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mandibular anaesthesia
Description: Inferior alveolar nerve block by direct standart method
Study: NCT03084731

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Directed Complementary Food (MDCF)
Description: For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Microbiota Directed Complementary Food (MDCF)
Description: For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.~Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period.
Study: NCT03601078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)
Study: NCT01266980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled FF/ GW642444M (200/25mcg)
Description: All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled FF/ GW642444M (200/25mcg)
Description: All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
Study: NCT04722393

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise training
Study: NCT02429427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
Study: NCT02136992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pirfenidone
Description: Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
Study: NCT03601078

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bb2121
Description: bb2121 consists of autologous T lymphocytes transduced with an anti-BCMA CAR lentiviral vector to express a chimeric antigen receptor targeting the human B cell maturation antigen (anti-BCMA CAR)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalomide
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talquetamab
Description: Specified dose on specified days
Study: NCT03061097

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous fecal microbiota transplant (Auto-FMP Enema)
Description: FMT is the process by which processed donor microbiota material is transplanted into recipients. The aim is to reconstitute the normal intestinal microbial flora in recipients. In this study, the fecal microbiota preparation will be made from the participant's own stool and processed into an auto-FMP enema formulation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Enema Preparation
Description: The placebo enema preparation will be identical in appearance but will not contain human feces to prevent unmasking of the trial arms.
Study: NCT00610623

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Description: 300 mg/day, IV from day 1 to 20

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: once per day, IV from day 1 to 20
Study: NCT00958789

Intervention type: DEVICE
Group type: OTHER
Intervention: Triathlon TS Knee System
Description: Total knee replacement for revision cases
Study: NCT04233463

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Modulen
Description: Crohn patients will be given Modulen, an oral polymeric diet enriched with TGF-beta 2, along with a tailored diet
Study: NCT04678128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance4Healing Telehealth Live Zoom Sessions
Description: Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dance4Healing Telehealth Live Zoom Sessions
Description: Week 1: 2-hour introduction session on Zoom platform with a live dance instructor at the participant's desired level of activity intensity (low, mild, or moderate).~Weeks 2-8: All participants will be asked to participate in a 1 hour online, instructor-led live class.
Study: NCT02136992

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pirfenidone
Description: Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
Study: NCT04678128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dance Buddy
Description: Following randomization (beginning of intervention period) half of the participants will be assigned a dance buddy, and will be asked to dance with their buddies using the Dance4Healing TLVP at least 2 additional times/week. This group will have 24/7 access to Dance4Healing Platform during the intervention and post-intervention periods.
Study: NCT02136992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo will be taken two tablets 3 times a day during the whole study process

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo will be taken two tablets 3 times a day during the whole study process
Study: NCT01502527

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Femarelle
Description: Twice daily oral treatment with Femarelle
Study: NCT04053504

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Teamwork-Peer Delivery
Description: Children with T1D and their parent will participate in 6 in-person FT-P group sessions during a 12-month period. Parents will also participate in monthly telephone support calls with a Parent Leader during the 12-month intervention period.
Study: NCT00153231

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVS
Description: Infracoccygeal sacropexy
Study: NCT02429427

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two capsules once daily with food
Study: NCT00782925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational program
Description: Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
Study: NCT04233463

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide
Description: Standard treatment for mild Crohn Disease patients
Study: NCT02436252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DSP-7888
Description: 3.5-10.5 mg/body,Id every 2-4 weeks
Study: NCT00782925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise program
Description: The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self-led exercises
Description: Self-led exercises to perform as part of a daily exercise routine
Study: NCT03872401

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered subcutaneously using an autoinjector pen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously using an autoinjector pen.
Study: NCT03919253

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: pyrotinib maleate tablets+nab-paclitaxel
Description: pyrotinib maleate tablets: 400mg orally once daily continunously nab-paclitaxel: 125mg/m2 iv d1、8 of each 21 day cycle, 6cycles.
Study: NCT03251014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YSS
Description: Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: YSS
Description: Intervention providing steamed whole YSS (\~265 g/day, 3 days/week) for eight weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmon
Description: Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Salmon
Description: Intervention providing steamed salmon fillet (\~246 g/day, 3 days/week) for eight weeks
Study: NCT00292474

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: percutaneous coronary intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: percutaneous coronary intervention
Study: NCT02956174

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Co-Cr single crown

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Periodontal parameters

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Periodontal parameters
Study: NCT03823937

Intervention type: OTHER
Intervention: Sniffin' Sticks test and Taste strips
Description: Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth.

Intervention type: OTHER
Intervention: Sniffin' Sticks test and Taste strips
Description: Sniffin' Sticks test (Burghardt®, Wedel, Germany) is a psychophysical test. It allows semi-objective assessment of the patient's olfactory performance by means of 3 subtests: threshold test, identification test and discrimination test. The Sniffin' Sticks Olfactory Test Kits contain pen like bodies as, for example, in pens used to write on flipcharts or whiteboards.These pen-like bodies, however, contain a fibre stick which is filled with scents. For testing, the cap should be removed so the patient can smell on the tip of the pen.~The taste strips are a validated examination procedure to investigate the taste ability. When testing the whole mouth taste ability, the taste strips are applied by putting them on the tongue and closing the mouth.
Study: NCT04250298

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: sucrosomal iron
Description: oral intake of iron as sachets or capsules
Study: NCT03075397

Intervention type: OTHER
Group type: OTHER
Intervention: blood sample
Description: A sample of HIV-1 infected patients's blood is collected

Intervention type: OTHER
Group type: OTHER
Intervention: sperm sample
Description: A sample of HIV-1 infected patients's sperm is collected
Study: NCT00153231

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sacrospinofixation
Study: NCT01550510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascorbic Acid
Description: 3x a week for 9 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 350mg/m2 once a week every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan
Description: 350mg/m2 once a week every 3 weeks
Study: NCT01582581

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephonic CBT
Description: Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Wait List Control
Description: Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
Study: NCT03770702

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Angiotensin receptor blockers
Description: Candesartan